🎯 Single-cell and spatial profiling of advanced PDAC revealed a CD276-shaped chemo-resistant niche, promoting basal-like state and immune suppression. CD276 is a promising therapeutic target.
🔗 https://ow.ly/f1Ww50YEsPx

4️⃣ Combination strategies (orthogonal vs vertical) to ⬆️ efficacy & ⬇️ resistance

3️⃣ Importance of understanding mechanism of resistance

2️⃣ Current evidence of approved vs emerging RASi across multiple cancer types (PDAC, colorectal, NSCLC)

Learned a lot on RAS inhibitors from @danafarbernews.bsky.social's Alice Shaw MD, PhD!

1️⃣ Differences in mechanism of actions

In a cohort of 1,066 patients, the protein-biomarker test PancreaSure distinguished Stage 1 and 2 pancreatic ductal adenocarcinoma from high-risk controls with 78.5% sensitivity and 93.5% specificity. Read more at https://ow.ly/a3OY50YbP8I

More 📸

@esge-news.bsky.social

Important approach considerations for SELs:

1️⃣ Location is crucial
2️⃣ EUS still the diagnostic cornerstone
3️⃣ Bite-on-bite biopsy has lowest dx yield
4️⃣ AI assisted EUS is promising, but still evolving

Association of Pancreatic Cancer with Acute Pancreatitis: A Systematic Review and Meta-Analysis
Lee, et al.

➡️ doi.org/10.14309/ctg.0000000000000927

Important reminder as endoscopic procedures gets more advanced, the simple ones are not risk-free

P1 and P2 lesions

Interesting findings from Onishi et al. on prediction of small bowel (SB) bleeding.

Study population:
Pts w/ susp. SB bleeding undergoing capsule or balloon-assisted endoscopy

1️⃣ Saurin P1 lesions predicts rebleeding rates
2️⃣ Prior endoscopic tx and antiplatelet use also predictors of rebleeding

A 5★ new review of the GLP-1 drugs, what they have achieved, and where the field is headed with so many new molecules and combinations
@thelancet.com

thelancet.com/journals/lan...

💡#RCT in cirrhosis: 6-mm TIPS lowers overt HE risk vs 8-mm, but increases rebleeding. Survival similar for both. Choosing the right size matters!

🔗: https://ow.ly/X6w450XSVzA